期刊文献+

大肠埃希菌、肺炎克雷伯菌产超广谱β-内酰胺酶检测及药敏分析 被引量:1

Detecting and analyzing antibiotic susceptibility of extended - spectrum β - lactamase - producing in E. Coli and Klebsiella pneumoniae
下载PDF
导出
摘要 目的统计分析肠杆菌科中的大肠埃希菌和肺炎克雷伯菌产超广谱'李云。-内酰胺酶(ESBLs)检出率和药敏情况,为临床提供合理使用抗生素用药依据。方法本文收集笔者所在医院2006年1月-2009年9月门诊和住院患者各种临床标本检出的大肠埃希菌200例,肺炎克雷伯菌99例,统计分析产ESBLs阳性率及药敏试验。结果产ESBLs大肠埃希菌、肺炎克雷伯菌的阳性检出率分别为69.5%和48.5%,其药敏:对阿米卡星、哌拉西林/他唑巴坦、头孢哌酮/舒巴坦的敏感率分别为:84.9%和89.6%、84.O%和75.0%、66.2%和79.2%。结论产ESBLs菌的检测,对指导临床用药有重要的意义。 Objective Analyzing the positive detectable rate and antibiotic susceptibility of extended - spectrum β - lactamase - producing in E. Coli and Klebsiella pneumoniae, provides clue for intelligent use of antibiotic in clinic. Methods 200 strains of E. Coli and 99 strains of Klebsiella pneumoniae isolated from clinical samples of outpatients and inpatients in our hospital from January 2006 to September 2009 were collected in this paper, the positive detectable rate and drug sensitivity of ESBLs -producing enterobacteria were analyzed with Statistical methods. Results The positive detectable rate of ELBS - producing in E. Coli and Klebsiella pneumoniae was 69.5% and 48.5% . There were 3 antimicrobials to which the sensitive rates of ELBS - producing in E. Coli and Klebsiella pneumoniae ,to Amikacin being 84.9% and 89.6%, to piperacillin - tazobactam being 84% and 75 %, to Cefoperazone - Sulbactam being 66.2% and 79.2% . Conclusion Detecting ESBLs -pro ducing enterobaeteria has important meaning for clinical aoolication.
出处 《中外医学研究》 2010年第5期20-21,共2页 CHINESE AND FOREIGN MEDICAL RESEARCH
关键词 大肠埃希菌 肺炎克雷伯菌 超广谱Β-内酰胺酶 药敏 E. Coli Klebsiella pneumoniae Extended - spectrum β- lactamase Antibiotic susceptibility
  • 相关文献

参考文献5

二级参考文献26

  • 1刘学东,胡必杰,高晓东,倪才妹,谢红梅.大肠埃希菌的耐药特性及其产超广谱β-内酰胺酶的分析[J].基础医学与临床,2004,24(3):314-316. 被引量:12
  • 2裴保香,郭绍来,王睿,周筱青.大肠埃希菌耐药性与头孢菌素类用量变化的相关性分析[J].中华医院感染学杂志,2004,14(4):373-376. 被引量:35
  • 3National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing[S]. Ninth informational supplement M100-S9. NCCLS, 1999.19(1):72-75.
  • 4Schroeder CM, Meng JH, Zhao SH,et al.Antimicrobial resistance of Escherichia coli O26,O103,O111,O128, and O145 from animals and humans[J]. Emerg Infect Dis,2002,8(12):1409-1414.
  • 5张云仙.泌尿系统感染病原菌分布及对喹诺酮类药的耐药性变迁[J].中国误诊学杂志,2003,4(3):578-579.
  • 6National Committee for Clinical Laboratory Standards. Performance standard for antimicrobial susceptibility testing[S].Twelfth informational supplement(M100-S12). Wayne, Pennsylvania: NCCLS, 2002.
  • 7Colodner R.Extended-spectrum beta-lactamases:a challenge for clinical microbiologists and infection control specialists[J].Am J Infect Control,2005,33(2):104-107.
  • 8Mendelson G,Hait V,Ben-Israel J,et al.Prevalence and risk factors of extended-spectrum beta-lactamases-producing Escherichia coli and Klebsiella pneumoniae in an Israeli longterm care facility[J].Eur J Clin Microbiol Infect Dis,2005,24(1):17-22.
  • 9Troche G,Joly LM,Guibert M,et al.Detection and treatment of antibiotic-resistant bacterial carriage in a surgical intensive care unit:a 6-year prospective survey[J].Infect Control Hosp Epidemiol,2005,26(2):161-165.
  • 10齐俊英 万齐全 陈如.外源指导序列转换临床耐药大肠埃希菌表型研究.中华医院感染学杂志,2003,13(4):305-307.

共引文献176

同被引文献12

引证文献1

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部